Jeremy Force

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 6

Top Topics

Neoadjuvant Chemotherapy

Metastatic Breast Cancer

Sentinel Lymph Node

Top Venues

NPJ breast cancer

Current treatment options in oncology

Breast cancer research and treatment

This page only lists publications with an associated author ORCID identifier.

Publications

Foluso O Ademuyiwa, Feng Gao, Cherease R Street, Ina Chen, Donald W Northfelt, Robert Wesolowski, Mili Arora, Adam M Brufsky, E Claire Dees, Cesar A Santa-Maria, Caitriona Cahir, Jeremy Force, Alvaro Moreno-Aspitia, John M Herndon, Madelyn Carmody, Sherri R Davies, Sarah Larson, Kathleen L Pfaff, Stephanie M Jones, Jason L Weirather, Anita Giobbie-Hurder, Scott J Rodig, Zheng Liu, Ian S Hagemann, Elad Sharon, William E Gillanders
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. NPJ breast cancer 8 (1) (2022)
Sarah E Burnette, Emily Poehlein, Hui-Jie Lee, Jeremy Force, Kelly Westbrook, Heather B Moore
Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer. Breast cancer research and treatment (2022)
Foluso O Ademuyiwa, Feng Gao, Cherease R Street, Ina Chen, Donald W Northfelt, Robert Wesolowski, Mili Arora, Adam M Brufsky, E Claire Dees, Cesar A Santa-Maria, Caitriona Cahir, Jeremy Force, Alvaro Moreno-Aspitia, John M Herndon, Madelyn Carmody, Sherri R Davies, Sarah Larson, Kathleen L Pfaff, Stephanie M Jones, Jason L Weirather, Anita Giobbie-Hurder, Scott J Rodig, Zheng Liu, Ian S Hagemann, Elad Sharon, William E Gillanders
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. NPJ breast cancer 8 (1) (2022)
Foluso O Ademuyiwa, Feng Gao, Cherease R Street, Ina Chen, Donald W Northfelt, Robert Wesolowski, Mili Arora, Adam M Brufsky, E Claire Dees, Cesar A Santa-Maria, Caitriona Cahir, Jeremy Force, Alvaro Moreno-Aspitia, John M Herndon, Madelyn Carmody, Sherri R Davies, Sarah Larson, Kathleen L Pfaff, Stephanie M Jones, Jason L Weirather, Anita Giobbie-Hurder, Scott J Rodig, Zheng Liu, Ian S Hagemann, Elad Sharon, William E Gillanders
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. NPJ breast cancer 8 (1) (2022)
Foluso O Ademuyiwa, Feng Gao, Cherease R Street, Ina Chen, Donald W Northfelt, Robert Wesolowski, Mili Arora, Adam M Brufsky, E Claire Dees, Cesar A Santa-Maria, Caitriona Cahir, Jeremy Force, Alvaro Moreno-Aspitia, John M Herndon, Madelyn Carmody, Sherri R Davies, Sarah Larson, Kathleen L Pfaff, Stephanie M Jones, Jason L Weirather, Anita Giobbie-Hurder, Scott J Rodig, Zheng Liu, Ian S Hagemann, Elad Sharon, William E Gillanders
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. NPJ breast cancer 8 (1) (2022)
James Isaacs, Carey Anders, Heather McArthur, Jeremy Force
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. Current treatment options in oncology 22 (5) (2021)